Latham & Watkins

Connected With Latham

Business EN ↓ 131 episodes

In each episode of Connected With Latham, we discuss ideas, developments, and trends shaping the global economy.

Be sure to visit the podcast's website and support the creator: connectedwithlatham.lathamwatkins.libsynpro.com

Author

Latham & Watkins

Category

Business

Latest episode

Nov 16, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Episode 106 – The FDA's New Playbook: Biosimilars, National Priority Vouchers, and the Plausible Mechanism Pathway 15.12.2025

Recent FDA actions are reshaping key aspects of drug and biologic development, including the Commissioner's National Priority Voucher program, the "plausible mechanism" pathway for personalized therapies, and new draft guidance aimed at streamlining biosimilars and interchangeables. Join Washington, D.C. partner Nathan Beaton and counsel Monica Groat and Chad Jennings as they discuss how these mov...

Episode 105 – Drug Pricing and Market Access: Government Pricing Assessment Expectations and Benefits 24.11.2025

Government pricing assessments are an important tool to help pharmaceutical manufacturers review their government price reporting function. They can also help uncovering strategic benefits and opportunities. In this episode of Connected With Latham, Eliza Biedziak , Managing Director at Ernst & Young LLP, joins Washington, D.C.  partner Chris Schott and associate Danny Machado to explore how these...

Episode 104 – Drug Pricing and Market Access: Deep Dive on the FDA Commissioner's National Priority Voucher Program Awards 03.11.2025

The new FDA Commissioner's National Priority Voucher (CNPV) pilot program promises to reduce recipients' application review times from 10-12 months to just 1-2 months. As part of the Trump administration's push for most favored nation (MFN) pricing, drug affordability is one criterion for vouchers, marking FDA's entry into the drug pricing fray. In this episode of Connected With Latham, Washington...

Episode 103 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit 02.10.2025

Stakeholders from across the healthcare industry — from manufacturers and consultants to outside counsel and government officials — recently convened in Chicago for the Medicaid Drug Rebate Program Summit 2025. In this episode of Connected With Latham, Washington, D.C. partner Chris Schott , counsel Nicole Liffrig Molife , and associate Danny Machado share impressions and key takeaways from the co...

Episode 102 – EU Data Act: Spotlight on Switching Requirements for Data Processing Services 11.09.2025

In this episode of Connected With Latham , London partner Fiona Maclean , Paris partner Jean-Luc Juhan , and London counsel Alain Traill discuss significant new switching requirements due to take effect for data processing services under the EU Data Act.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship betwee...

Episode 101 – EU Data Act: Implications for Data Privacy and Cybersecurity 10.09.2025

In this episode of Connected With Latham , London partner Gail Crawford and Frankfurt partner Tim Wybitul discuss the EU Data Act, and what this means for data privacy and cybersecurity practices.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send co...

Episode 100 – The Leeds Reforms: Implications for UK Financial Services 17.07.2025

In this episode of Connected with Latham , London partners Rob Moulton and Nicola Higgs discuss the UK government's plans for the financial services sector, and key takeaways for financial services firms.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not...

Episode 99 – Drug Pricing: Takeaways from the Philadelphia Pricing and Contracting USA Conference 24.06.2025

Current developments, such as most favored nation (MFN) pricing, grabbed much of the spotlight when key industry stakeholders met in Philadelphia for the Pricing and Contracting USA Conference. In this episode of Connected With Latham , Allan Thoen, Director & Associate General Counsel with Sandoz, joins Washington, D.C. partner Chris Schott and associate Danny Machado to discuss impressions and t...

Episode 98 – Drug Pricing: Takeaways from the MDMA Annual Meeting 06.06.2025

Stakeholders from across the healthcare industry, including members of Congress, the US Food and Drug Administration, and the Center for Medicare and Medicaid Services, recently convened in Washington D.C. for the Medical Device Manufacturers Association (MDMA) Annual Meeting. In this episode of Connected With Latham, Washington, D.C. partners Chris Schott , Nate Beaton , and Bill McConagha , and...

Episode 97 – Drug Pricing: How the Drug Pricing EO Impacts FDA and Overlaps with Grassley-Led Legislation 02.05.2025

The "Lowering Drug Prices by Once Again Putting Americans First" Executive Order addresses various FDA matters, such as importation from Canada and accelerated approval of generics and biosimilars. In this episode of Connected With Latham , Washington, D.C. partners Chris Schott , Ben Haas , and Bill McConagha analyze these FDA implications, and explore how the EO overlaps with  five drug pricing...

Episode 96 – The Growth Rocketship: Shield AI's Takeoff Shows What's Possible in Defensetech 30.04.2025

Founded in 2015, Shield AI uses technology and intelligence systems to protect service members and civilians. The venture-backed unicorn's flagship autonomy software, Hivemind, powers aircraft, drones, and other platforms to reliably support complex missions in contested environments. Latham represented Shield AI on its US$240 million strategic funding round, raising the company's valuation to US$...

Episode 95 – Drug Pricing: FDA in the Age of Executive Orders and DOGE 12.03.2025

The initial months of the Trump administration have been marked by a flurry of executive orders and significant activity by the Department of Government Efficiency (DOGE). The US Food and Drug Administration is a key target of these efforts. In this episode of Connected With Latham , Washington, D.C. partners Chris Schott  and Ben Haas and associate Danny Machado explore how FDA may be affected, p...

Episode 94 – Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook 25.02.2025

Stakeholders from across the healthcare and biopharmaceutical industry recently convened in San Francisco for the annual J.P. Morgan Healthcare Conference. In this episode of Connected With Latham, Washington, D.C. partners  Chris Schott and Jason B. Caron and associate Danny Machado share key takeaways from the conference, including a renewed optimism from the dealmaking world and the healthcare...

Episode 93 – EU's Digital Operational Resilience Act: What You Should Know and How to Stay Compliant 16.01.2025

The deadline for the EU's Digital Operational Resilience Act (DORA) has arrived. This regulation applies to most financial entities operating in the EU market and impacts a broad range of third-party providers of technology-related services. In this episode of Connected with Latham , Christian McDermott and Alain Traill explore the key changes introduced by DORA, its broad territorial scope, the t...

Episode 92 – UK FinReg Focus Areas in 2025: Sectoral Trends 06.01.2025

In this episode of Connected with Latham, the final of three episodes complementing Latham's "10 Key Focus Areas for UK-Regulated Financial Services Firms in 2025" report, London partners  Rob Moulton and Nicola Higgs and counsel Becky Critchley discuss the key cross-sector trends for financial services firms in 2025. They provide their thoughts on what firms need to be thinking about in relation...

Episode 91 – UK FinReg Focus Areas in 2025: Retail Markets 06.01.2025

In this episode of Connected with Latham, the second of three episodes complementing Latham's "10 Key Focus Areas for UK-Regulated Financial Services Firms in 2025" report, London partners Rob Moulton and Nicola Higgs and counsel Becky Critchley discuss the upcoming reform agenda for retail markets in 2025. They break down the difficult challenge of balancing risk-taking and growth with consumer p...

Episode 90 – UK FinReg Focus Areas in 2025: Wholesale Markets 06.01.2025

In this episode of Connected with Latham , the first of three episodes complementing Latham's "10 Key Focus Areas for UK-Regulated Financial Services Firms in 2025" report, London partners Rob Moulton and Nicola Higgs and counsel Becky Critchley discuss what will likely appear on the reform agenda for wholesale markets in 2025. They examine capital markets reforms, changes to the remuneration rule...

Episode 89 – The Growth Rocketship: How BridgeBio's Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech – Then, Now, and What's Next? 30.12.2024

In this episode of Connected With Latham , Haim Zaltzman , Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with BridgeBio 's Co-Founder and Chief Executive Officer Neil Kumar and Chief Financial Officer Brian Stephenson. Since 2015, BridgeBio, a commercial-stage biopharmaceutical, has maintained a mission to discover, create, test, and deliver transformative medicines...

Episode 88 – Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities? 16.12.2024

FDA enforcement activities range from administrative actions like conducting establishment inspections and issuing warning letters to judicial enforcement through the Department of Justice, which can take the shape of civil or criminal actions. While we can expect the agency's core activities to continue, its priorities may shift under the incoming Trump Administration. One point of emphasis might...

Episode 87 – Drug Pricing: What's In the New CMS Medicaid Final Rule? 25.11.2024

The Centers for Medicare & Medicaid Services (CMS) recently published its final rule to implement the Medicaid Services Investment and Accountability Act of 2019 (MSIAA). The final rule significantly deviates from the agency's 2023 proposal, with CMS backing off from "follow the pill" best price stacking, subjecting certain vaccines to Medicaid rebates, and creating a "shame list" of high-cost Med...

Episode 86 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit 18.10.2024

Manufacturers, government officials, and other stakeholders recently convened in Chicago for the annual Medicaid Drug Rebate Program Summit. In this episode of Connected with Latham, Washington, D.C. associate  Danny Machado interviews partner Chris Schott about takeaways from the conference, including thoughts on the new Medicaid regulation that CMS released just days before the conference.   Thi...

Episode 85 – Drug Pricing: How The Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry 19.09.2024

Recent Supreme Court decisions, such as the opinions in Loper Bright Enterprises v. Raimondo and Relentless v. Department of Commerce that overruled the long-standing Chevron doctrine, will likely impact how federal agencies interpret ambiguous statutes when regulating the pharmaceutical industry. And in Securities & Exchange Commission v. Jarkesy , the Court established a right to a jury trial fo...

Episode 84 – Pro Bono: Shabir Kabiri's Remarkable Journey from Afghanistan to Asylum in the US 20.08.2024

In this episode of Connected with Latham , we explore the remarkable story of Shabir Kabiri, an Afghan refugee who secured asylum in the United States with the help of a Latham pro bono team. Shabir shares his harrowing journey, his time as a cadet at West Point, and the dangers he faced upon returning home. When Kabul fell to the Taliban in 2021, Shabir experienced the chaos and fear firsthand, a...

Episode 83 – Drug Pricing: How Are Payers Responding to the IRA? 19.08.2024

The US healthcare landscape is undergoing significant changes as the Centers for Medicare & Medicaid Services (CMS) continues to implement the Inflation Reduction Act (IRA). One key stakeholder group affected by the IRA drug price negotiations and Medicare Part D redesign are health insurance companies. In this episode of Connected with Latham, we delve into how these payers are responding to the...

Episode 82 – Drug Pricing: Takeaways from the New Orleans Pricing and Contracting USA Conference 21.06.2024

Current developments grabbed much of the spotlight when key industry stakeholders met in New Orleans for the Pricing and Contracting USA Conference. In this episode of Connected With Latham , Washington, D.C. partner Chris Schott and associates Danny Machado and Elisabeth Crusey share their observations from the conference, concluding with four calls to action for pharmaceutical manufacturers.   T...

Listen to the Connected With Latham podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.